88
K. Tsuji et al. / Bioorg. Med. Chem. Lett. 12 (2002) 85–88
5. Tarkowski, A.; Gunnarsson, K.; Stalhandske, T. Immunol-
ogy 1986, 59, 589.
compounds was further confirmed by combustion analysis (C,
H, N within 0.4%). 7a: mp 200–202 ꢂC (dec); IR(Nujol) 1650,
6. Karussis, D. M.; Lehmann, D.; Slavin, S.; Vourka-Kar-
ussis, U.; Mizrachi-Koll, R.; Ovadia, H.; Kalland, T.;
Abramsky, O. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6400.
7. Karussis, D. M.; Lehmann, D.; Slavin, S.; Vourka-Kar-
ussis, U.; Mizrachi-Koll, R.; Ovadia, H.; Ben-Num, D.; Kal-
land, T.; Abramsky, O. Ann. Neurol. 1993, 34, 654.
8. Anderson, O.; Lycke, J.; Tollesson, P. O.; Svenningsson,
A.; Runmarker, B.; Linde, A. S.; Astrom, M.; Gjorstrup, P.;
Ekholm, S. Neurology 1996, 47, 895.
9. Karussis, D. M.; Meiner, Z.; Lehmann, D.; Gomori, J.-M.;
Schwaz, A.; Linde, A.; Abramsky, O. Neurology 1996, 47, 341.
10. Nived, O.; Sturfelt, G.; Nilsson, B.; Termander, B.; Gun-
narsson, P. O.; Strandgarden, K.; Wollheim, F. Int. J.
Immunother. 1994, 10, 49.
1635, 1615, 1590, 1565, 1500 cmꢀ1 1H NMR(DMSO-d6) d
;
2.49 (3H,s), 3.29 (3H,s), 3.42 (3H,s), 7.0–7.8 (8H,m), 11.3
(1H,s); MS m/z 354 (M+), 247. Anal. calcd for C19H18N2O3S:
C, 64.39; H, 5.12; N, 7.91. Found: C, 64.54; H, 5.07; N, 7.69.
Complete physicochemical data and experimental details are
disclosed in the following patent: Matsuo, M.; Tsuji, K.;
Nakamura, K.; Spears, G. W. WO92-18483, 1992; Chem.
Abstr. 1993, 118, 212903b.
21. Abbreviations : DMA, N,N-dimethylacetamide; DMF,
N,N-dimethylformamide; DMAP, 4-(dimethylamino)pyridine;
m-CPBA, m-chloroperbenzoic acid; WSCD, 1-(3-dimethyla-
minopropyl)-3-ethylcarbodiimide.
22. Heilbron, I. M.; Kitchen, F. N.; Parkes, E. B.; Sutton,
G. O. J. Chem. Soc. 1925, 2171.
11. Bergh, J.; Totterman, T.; Nilsson, S.; Ahlbom, H.; Lars-
son, S.-G.; Jansson, T.; Letocha, H.; Termander, B.; Svedberg;
Strandgarden, K.; Gunnarsson, P. O.; Nilsson, B. Eur. J.
Cancer 1991, 27 (Suppl. 2), 195.
23. Hardtmann, G. E.; Koletar, G.; Pfister, O. R. J. Hetero-
cycl. Chem. 1975, 12, 565.
24. Eriksoo, E.; Sandberg, E. B. M.; Stalhandske, T.
EP59698, 1982; Chem. Abstr. 1983, 98, 34513h.
12. Bengtsson, M.; Simonsson, B.; Carlsson, K.; Nilsson, B.;
Smedmyr, B.; Termander, B.; Oberg, G.; Totterman, T.
Transplantation 1992, 53, 882.
13. (a) Rowe, J.; Nilsson, B.; Simonsson, B. Leuk. Lymph.
1993, 11, 321. (b) Rowe, J.; Ryan, D.; Dipersio, J.; Gaspari,
A.; Nilsson, B.; Larsson, L.; Liesveld, J.; Kouides, P.;
Simonsson, B. Stem Cells 1993, 11 (Suppl. 3), 34.
14. Kalland, T.; Alm, G.; Stalhandske, T. J. Immunol. 1985,
134, 3956.
15. Wanders, A.; Vogt, P.; Karlsson-Parra, A.; Wonigkeit, K.;
Gerdin, B.; Tufveson, G. Transplantation 1991, 52, 234.
16. Khan, S. R.; Mhaka, A.; Pili, R.; Isaacs, J. T. Bioorg.
Med. Chem. Lett. 2001, 11, 451.
17. Ogino, T.; Tsuji, K.; Tojo, T.; Igari, N.; Seki, N.; Sudo,
Y.; Manda, T.; Nishigaki, F.; Matsuo, M. Bioorg. Med. Chem.
Lett. 1998, 8, 75.
25. Six-week-old female (C57BL/6ꢁDBA/2)F1 and DBA/2
mice were used. Chronic GVHD was induced in (C57BL/
6ꢁDBA/2)F1 mice with two injections of DBA/2 spleen cells
given 5 days apart. Each injection contained 5ꢁ107 cells. From
3 days after the second cell injection, drug was administered
orally once a day for 8 weeks. To assess the renal disease,
proteinuria were measured after the last drug administration.
The concentration of serum albumin in the urine was deter-
mined by the single radial immunodiffusion method using
rabbit anti-mouse serum albumin antiserum. Ten mice were
used per group. The activity was expressed as a % inhibition
of proteinuria.
As an indication of autoimmune disease, 4 weeks after the
last cell injection anti-DNA antibodies were measured by
ELISA.27
26. The sulfoxide 8a was easily metabolized to the corre-
sponding sulfide 7a in mice, while 7a was unexpectedly stable
in vivo (mice, rats and dogs).
18. Bruijn, J. A.; van Elven, E. H.; Hogendoorn, P. C. W.;
Corver, W. E.; Hoedemaeker, P. J.; Fleuren, G. J. Am. J.
Pathol. 1988, 130, 639.
19. Bruijn, J. A.; Hogendoorn, P. C. W.; Corver, W. E.; van
den Broek, L. J. C. M.; Hoedemaeker, P. J.; Fleuren, G. J.
Clin. Exp. Immunol. 1990, 79, 115.
27. Fujitsu, T.; Sakuma, S.; Seki, N.; Senoh, H.; Mori, J.;
Kikuchi, H. Int. J. Immunopharmacol 1986, 8, 897.
28. Evaluated by histopathological examination in a blinded
fashion.
20. All new compounds reported herein showed satisfactory
spectral data (1H NMR, IR and MS). The purity of all target
29. Okumura, M.; Kanayama, Y.; Amatsu, K.; Negoro, N.;
Kohda, S.; Takeda, T.; Inoue, T. Ann. Rheum. Dis. 1993, 52, 14.